The results found that patients taking tirzepatide over a yearlong span were much likelier to achieve a weight loss of 10 percent or higher compared to those taking semaglitude. After the year was up, the patients on tirzepatide lost up to 15 percent of their body weight while the other group on Ozempic or Wegovy only lost eight percent.

Weight-loss drugs are taking a big bite out of the food business. People taking meds like Ozempic, Mounjaro and Wegovy — originally developed to treat Type 2 diabetes — spend less on groceries and have a healthier assortment in their basket,

GLP-1 drugs like Ozempic, Mounjaro, Zepbound and Wegovy are being explored for treating an array of conditions including sleep apnea, kidney disease, addiction, Parkinson’s and Alzheimer’s.

New study finds patients taking Mounjaro are 3 times as likely to lose 15 percent or more of their bodyweight as those taking Ozempic.

US health regulators warned that patients may be injecting themselves with incorrect amounts of copycat weight-loss drugs, causing harm that has landed some in the hospital.

Prospective competitors to newly popular anti-obesity and anti-diabetes drugs are heading toward commercialization. Why it matters: Booming sales of Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have led to widespread shortages of GLP-1 treatments.

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to shed excess pounds, you might be wondering if the injectable medication Ozempic is right for you — and if so,

Find out how Ozempic, Mounjaro, and other medicines are helping to revolutionize weight loss around the world... and how much people are willing to pay for them.